Oct 26, 2026
•
11 min read
Divarasib beat the approved KRAS drugs head to head, Moderna fell on a win, and Lycia debuted up 66.7%.
Oct 23, 2026
10 min read
The FDA cleared Ultomiris in IgA nephropathy, Biohaven's ataxia drug got a second review, and QIAGEN's first session was quiet.
Oct 22, 2026
Abbott is splitting in two, EQT is taking QIAGEN private at a 40 percent premium, and brepocitinib swept both Phase 3 uveitis trials.
Oct 21, 2026
9 min read
GSK landed the first finite course functional cure option in hepatitis B, Disc raised $450 million overnight, and Alcon paid $550 million for Neurotech.
Roche licensed Hansoh's ADC engine without buying it, Merck KGaA bought Silence outright, and Disc and Veradermics both won Phase 3.
Medtronic completed its exit, China proposed platform export bans, City closed its debut up 24.4%, and the CHMP backed the first oral GLP-1 pill in the EU.
City priced an upsized $200 million IPO, Iambic closed up 18.2%, AstraZeneca signed insitro, and the week's clearing prices got their grade.
Anktiva clears by extrapolation, MiniMed's exchange closes at 18.3%, and the market grades Liquidia's peace and Biomea's pitch in one session.
J&J beat and raised and still fell, Liquidia ends the United Therapeutics war, and the IPF field sorts itself in one week.
A celiac drug class arrives, Bristol Myers withholds its numbers, and MiniMed's exchange runs five to one.
BRUNELLO's full table, three Friday approvals, a $1.1 billion close, and two Monday morning binaries.
A Phase 3 futility stop, a celiac win from a $2.2B bet, Viatris' $1.65B revenue deal, and the week's grade.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
